Human glioma immunobiology in vitro: implications for immunogene therapy.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Neurosurgery

• Publication date

  2000-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00006123-200005000-00030PMID 10807250
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of four human malignant glioma cell lines

  2004cited by this paper
• Improved Technique for Establishing Short Term Human Brain Tumor Cultures

  1999cited by this paper
• Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.

  1998cited by this paper
• Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro.

  1997cited by this paper
• Gene Therapy for Metastatic Brain Tumors by Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Tumor Cells

  1997cited by this paper
• Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model.

  1997cited by this paper
• Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

  1997cited by this paper
• Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors

  1997cited by this paper
• Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.

  1997cited by this paper
• Lipoxygenase inhibitors block CD95 ligand‐mediated apoptosis of human malignant glioma cells

  1997cited by this paper
• Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.

  1997cited by this paper
• Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

  1996cited by this paper
• Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.

  1996cited by this paper
• The expanding universe of T-cell subsets: Th1, Th2 and more.

  1996cited by this paper
• Expression and function of B7‐1 (CD80) and B7‐2 (CD86) on human epidermal Langerhans cells

  1996cited by this paper
• GM‐CSF‐induced in vivo expansion of splenic dendritic cells and their strong costimulation activity

  1996cited by this paper
• Molecular mechanisms of microglial activation.

  1996cited by this paper
• Novel costimulators in the immune gene therapy of cancer.

  1996cited by this paper
• Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA.

  1996cited by this paper
• Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.

  1995cited by this paper
• Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.

  1995cited by this paper
• Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production

  1995cited by this paper
• Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation?

  1995cited by this paper
• Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

  1995cited by this paper
• Interpreting MHC class I expression and class I/class II reciprocity in the CNS: Reconciling divergent findings

  1995cited by this paper
• Comparative analysis of B7‐1 and B7‐2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines

  1995cited by this paper
• CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.

  1995cited by this paper
• The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

  1995cited by this paper
• Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas.

  1995cited by this paper
• Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.

  1995cited by this paper
• Tumor necrosis factor alpha upregulates human microglial cell production of interleukin-10 in vitro

  1995cited by this paper
• Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B

  1995cited by this paper
• Mechanisms of lysis by cytotoxic T cells.

  1995cited by this paper
• Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.

  1995cited by this paper
• Liposomal transfection of human gamma-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells.

  1994cited by this paper
• Selective expression of interleukin-10 gene within glioblastoma multiforme.

  1994cited by this paper
• Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.

  1994cited by this paper
• Immunotherapy of malignant gliomas.

  1994cited by this paper
• In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2.

  1994cited by this paper
• CD28-B7 interactions in T-cell activation.

  1994cited by this paper
• Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.

  1994cited by this paper
• Coexpression of Interleukin-1β and Interleukin-6 in Human Brain Tumors

  1994cited by this paper
• Coexpression of interleukin-1 beta and interleukin-6 in human brain tumors.

  1994cited by this paper
• Costimulation of T cells for tumor immunity.

  1993cited by this paper
• Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

  1993cited by this paper
• Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

  1993cited by this paper
• Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

  1993cited by this paper
• A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

  1993cited by this paper
• Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity

  1993cited by this paper
• Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

  1992cited by this paper
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo.

  1992cited by this paper
• Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

  1991cited by this paper
• Modulation of T-cell function by gliomas.

  1991cited by this paper
• Human glioblastoma cells release interleukin 6 in vivo and in vitro.

  1990cited by this paper
• In vitro Prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes

  1990cited by this paper
• Immunohistochemical detection and correlation between MHC antigen and cell-mediated immune system in recurrent glioma by APAAP method.

  1990cited by this paper
• Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

  1989cited by this paper
• Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.

  1989cited by this paper
• Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors.

  1988cited by this paper
• Human glioma cell lines: tumour associated antigens distribution and sensitivity to antibody-toxin or ligand-toxin conjugates. A preliminary report.

  1988cited by this paper
• The glioblastoma‐derived t cell suppressor factor/ transforming growth factor‐β2 inhibits t cell growth without affecting the interaction of interleukin 2 with its receptor

  1988cited by this paper
• Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

  1986cited by this paper
• Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens.

  1985cited by this paper
• Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin.

  1984cited by this paper
• Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study

  1983cited by this paper
• Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells.

  1982cited by this paper

• Viruses in glioblastoma: an update on evidence and clinical trials

  2024cites this paper
• Highly Expressed CYBRD1 Associated with Glioma Recurrence Regulates the Immune Response of Glioma Cells to Interferon

  2021cites this paper
• Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

  2019cites this paper
• Expression of inhibitory checkpoint ligands by Glioblastoma Multiforme cells and the implications of an enhanced stem cell-like phenotype

  2019cites this paper
• Role of Kynurenine Pathway in Glioblastoma

  2017cites this paper
• LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4

  2017cites this paper
• A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors

  2016cites this paper
• RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells

  2015cites this paper
• Serum Level of Cytokines and their Expression in Brain Tumors (Meningioma and Glioma) of Iraqi Patients

  2015cites this paper
• Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.

  2015cites this paper
• Immune Response: Glioma-Associated Immunosuppression

  2014cites this paper
• Myeloid-derived suppressor cells in glioma

  2013cites this paper
• Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro

  2013cites this paper
• The Mechanism of the Initiation and Progression of Glioma

  2013cites this paper
• Myxoma Virus Infection Promotes NK Lysis of Malignant Gliomas In Vitro and In Vivo

  2013cites this paper
• Viral and Non-Viral Gene Therapy for Glioblastoma: New Insights into theTreatment of Malignant Brain Tumors

  2013cites this paper
• An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma

  2013cites this paper
• GLI2 Regulates TGF-β1 in Human CD4+ T Cells: Implications in Cancer and HIV Pathogenesis

  2012cites this paper
• Application of Carbon Nanotubes to Brain Tumor Therapy

  2012cites this paper
• Immunology of brain tumors.

  2012cites this paper
• Basic concepts in glioma immunology.

  2012cites this paper
• Antigen-receptor gene-modified T cells for treatment of glioma.

  2012cites this paper
• Galectins as Novel Targets for the Treatment of Malignant Gliomas

  2012cites this paper
• New perspectives in glioma immunotherapy.

  2011cites this paper
• Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions

  2011cites this paper
• Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System

  2011cites this paper
• Is HCMV a tumor promoter?

  2011cites this paper
• Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.

  2011cites this paper
• Inter feron -g amma in Brain Tumor

  2010cites this paper
• Multi-walled carbon nanotube (MWCNT) synthesis, preparation, labeling, and functionalization.

  2010cites this paper
• Interferon-gamma in brain tumor immunotherapy.

  2010cites this paper
• Mechanisms of local immunoresistance in glioma.

  2010cites this paper
• Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

  2010cites this paper
• Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation.

  2009cites this paper
• Immunotherapeutic approaches for glioma.

  2009cites this paper
• Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma

  2009cites this paper
• Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.

  2008cites this paper
• Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines

  2008cites this paper
• The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model

  2008cites this paper
• Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy

  2008cites this paper
• Current immunotherapeutic strategies for central nervous system tumors.

  2007cites this paper
• Immunotherapy for Gliomas: Part II Passive Immunotherapy and Active Immunotherapy

  2007cites this paper
• Generation of human innate immune responses towards membrane macrophage colony stimulating factor (mM-CSF) expressing U251 glioma cells within immunodeficient (NIH-nu/beige/xid) mice.

  2007cites this paper
• Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

  2006cites this paper
• Models of monocytic invasion into glioma cell aggregates.

  2006cites this paper
• Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-γ and -β

  2006cites this paper
• Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model

  2006cites this paper
• Immunotherapeutic Approaches for Alzheimer’s Disease

  2006cites this paper
• Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta.

  2006cites this paper
• Impaired capacity for upregulation of MHC class II in tumor‐associated microglia

  2005cites this paper
• Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

  2005cites this paper
• T cell activity in glioma chemoresponsiveness and genetics

  2005cites this paper
• Increased effi cacy of an interleukin-12- secreting herpes simplex virus in a syngeneic intracranial murine glioma model1

  2005cites this paper
• Dendritic cell vaccines and immunity in glioma patients.

  2005cites this paper
• Immunotherapy for malignant glioma: current approaches and future directions

  2005cites this paper
• Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12

  2005cites this paper
• Microglia Stimulate the Invasiveness of Glioma Cells by Increasing the Activity of Metalloprotease-2

  2005cites this paper
• Anti-CD 3 Anti-Epidermal Growth Factor Receptor ( EGFR ) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an AnimalModel

  2005cites this paper
• Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells.

  2005cites this paper
• Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain

  2005cites this paper
• The immunobiology of malignant gliomas.

  2005cites this paper
• CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis

  2004cites this paper
• The Innate Immune Response in the Central Nervous System and Its Role in Glioma Immune Surveillance

  2004cites this paper
• Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.

  2004cites this paper
• Human Alloreactive CTL Interactions with Gliomas and with Those Having Upregulated HLA Expression from Exogenous IFN-γ or IFN-γ Gene Modification

  2003cites this paper
• Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.

  2003cites this paper
• Expression and release of CD14 in astrocytic brain tumors

  2003cites this paper
• Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins

  2003cites this paper
• Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification.

  2003cites this paper
• Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme

  2002cites this paper
• Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas

  2002cites this paper
• Immune responses in glioblastoma: an avenue to effective cancer therapy or a mere epiphenomenon?

  2002cites this paper
• Non-cytotoxic Therapies for Malignant Gliomas

  2002influential citation
• Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12

  2002cites this paper
• Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas.

  2002cites this paper
• All in the head: obstacles for immune rejection of brain tumours

  2002cites this paper
• Human Brain Tumor Cell Culture Characterization after Immunostimulatory Gene Transfer

  2002cites this paper
• Clinical immunotherapy for brain tumors.

  2002cites this paper
• Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro.

  2002cites this paper
• Protective and Pathological Immune Responses in the CNS

  2002cites this paper
• Potential of gene therapy for brain tumors.

  2001cites this paper
• Changing boundaries in the treatment of malignant gliomas

  2001cites this paper
• Gene therapy of glioblastomas: from suicide to homicide.

  2001cites this paper
• Experimental findings in primary glioma cell cultures.

  2001cites this paper
• Immunomodulation of Glioma Cells after Gene Therapy: Induction of Major Histocompatibility Complex Class I but Not Class II Antigen in Vitro

  2001cites this paper
• New strategy developments in brain tumor therapy.

  2001cites this paper
• Role of microglia in glioma biology

  2001cites this paper
• Glioma immunology and immunotherapy.

  2000cites this paper
• Gene Gun Transfection of Human Glioma and Melanoma Cell Lines with Genes Encoding Human IL-12 and GM-CSF

  2000cites this paper